Related Experiment Videos
Visual acuity after radiation for orbital rhabdomyosarcoma
1Department of Ophthalmology, New York Hospital-Cornell Medical Center.
American Journal of Ophthalmology
|December 15, 1994
Summary
Orbital rhabdomyosarcoma treatment impacts vision. Most patients treated with radiation and chemotherapy experienced significant vision loss, with 66% having no light perception.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Radiation Oncology
Background:
- Orbital rhabdomyosarcoma is a rare but aggressive childhood cancer.
- Treatment often involves radiation therapy, sometimes with chemotherapy.
- Long-term outcomes, particularly visual function, require careful evaluation.
Purpose of the Study:
- To assess the long-term visual outcomes in patients with orbital rhabdomyosarcoma.
- To analyze the impact of radiation therapy (with or without chemotherapy) on vision.
Main Methods:
- Retrospective review of follow-up data for 32 patients.
- Patients treated between 1960 and 1992 with external beam radiation.
- Analysis of visual acuity after a 5- to 8-year follow-up period.
Main Results:
- Only 19% of patients achieved best-corrected visual acuity of 20/70 or better.
- 15% had visual acuity ranging from light perception to 20/300.
- A significant majority (66%) experienced no light perception.
Conclusions:
- Radiation therapy for orbital rhabdomyosarcoma is associated with substantial long-term visual impairment.
- Treatment decisions must consider the high risk of vision loss.
- Further research may explore strategies to mitigate ocular toxicity while maintaining oncologic control.